Germany Computer-Aided Drugs Discovery Market Market Report 2023 to 2030

Germany Computer-Aided Drugs Discovery Market Analysis

$ 3999

Germany Computer-Aided Drug Discovery Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Computer-Aided Drug Discovery is expanding as a result of growing prevalence of chronic diseases. This demand is fueling the development of better drug development through Computer-Aided Drug Discovery approaches. Some of the key players in the global Computer-Aided Drug Discovery Market include Charles River Laboratories, BOC Sciences, Bioduro-Sundia, Schrodinger, Inc., Aragen Life Sciences Pvt. Ltd., Aris Pharmaceuticals, Inc., Bayer AG, AstraZeneca plc, and Albany Molecular Research Inc. (AMRI).

ID: IN10DEHS039 CATEGORY: Healthcare Services GEOGRAPHY: Germany AUTHOR: Dr. Nensi Savani

Buy Now

Germany Computer-Aided Drugs Discovery Market Executive Summary

Germany Computer-Aided Drugs Discovery Market is valued at around $118.2 Bn in 2022 and is projected to reach $247.9 Bn by 2030, exhibiting a CAGR of 9.7% during the forecast period 2023-2030.

Increased prevalence of chronic and undiagnosed diseases is anticipated to accelerate the requirement for quick drug development, driving the expansion of the computer-aided drug discovery market over the horizon. Using a mix of tools, researchers and analysts can use the contemporary technique known as Computer-Aided Drug Discovery to analyse, design, develop, monitor, and investigate a three-dimensional structure of the target disease molecule and its complement biomolecule ligand. Researchers like this approach because it expedites research and drug discovery. Strategic partnerships between market participants and increased medicine demand are anticipated to drive the global market.

The increase in the application of artificial intelligence in drug development for polypharmacology, chemical synthesis, drug screening, and research is the primary driver driving the growth of the global Computer-Aided Drug Discovery market.

Pharmaceutical and biotechnology firms like Charles River Laboratories, BOC Sciences, Bioduro-Sundia, Schrodinger, Inc., Aragen Life Sciences Pvt. Ltd., Aris Pharmaceuticals, Inc., Bayer AG, AstraZeneca plc, and Albany Molecular Research Inc. (AMRI), are some of the major players in the Computer-Aided Drug Discovery Market.

Various methods have been used recently to determine which chemical compounds need to be created and marketed. Before being approved for use in humans, 5,000–10,000 medicines have recently undergone laboratory testing. The entire process can take up to 10 years or longer to create or find new medicines. Such factors are anticipated to accelerate the use of Computer-Aided Drug Discovery in the pharmaceutical business sector.

Drug development and design using the conventional method is a very costly and time-consuming process. From conception to approval, a new medication typically takes 10–14 years and billions of dollars to create. The amount of time needed for testing and experimentation significantly decreased when Computer-Aided Drug Discovery was introduced. The market value for Computer-Aided Drug Discovery is anticipated to rise due to the increased demand for quick pharmaceutical discovery for chronic diseases including cancer and diabetes.

Market Dynamics

Drivers of Germany Computer-Aided Drug Discovery Market:

Growing Incidence and Prevalence of Chronic Diseases: The need for medication research and development has increased as chronic diseases including cancer, diabetes, and cardiovascular disorders are becoming more common. Computer-Aided Drug Discovery approaches present a viable strategy to quicken medication development and boost clinical trial success rates.

Rapid Advancement in Pharmaceutical Development: More precise and effective drug screening and design are now possible because of the development of sophisticated Computer-Aided Drug Discovery tools and algorithms. As a result, the use of Computer-Aided Drug Discovery approaches in the drug development process has increased.

Increased Demand for Cost-Efficient and Time-Saving Drug Discovery: The market for sophisticated Computer-Aided Drug Discovery is being significantly stimulated by the rising demand for time- and money-saving methods of drug discovery. Using Computer-Aided Drug Discovery approaches, it is now possible to efficiently screen huge databases of chemical compounds, which saves time and money compared to using conventional drug discovery procedures.

Restraints of Germany Computer-Aided Drug Discovery Market:

Scarcity of Qualified Labor: A significant obstacle for the market is the lack of qualified workers in the Computer-Aided Drug Discovery industry. It takes specialised knowledge to create and use Computer-Aided Drug Discovery software and algorithms, which might be a barrier for some businesses.

High Cost of Computer-Aided Drug Discovery Software: The market has a major hurdle as a result of the high cost of Computer-Aided Drug Discovery software. For certain organisations, especially smaller businesses and academic institutions, the cost of Computer-Aided Drug Discovery software and hardware might be a barrier to admission.

Key players

BioSolveIT BioNTech AG Indivumed GmbH MAB Discovery GmbH Molecular Health GmbH Lead Discovery Center GmbH AiCuris Anti-infective Cures GmbH Numares AG AiM-Hi Technologies GmbH iThera Medical GmbH

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Germany Computer-Aided Drug Discovery Market

By Type:

Structure-Based Drug Design
Ligand-Based Drug Design
Sequence-Based Approaches

By Therapeutic Area:

Oncology
Neurology
Cardiovascular Disease
Respiratory Disease
Diabetes
Others

By End-user:

Pharmaceutical Companies
Biotechnology Companies
Research Laboratories

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.